非靶向代谢组学揭示与CYP3A抑制相关的新内源性血浆生物标志物
本研究在一项固定序列药物相互作用研究中,对11名健康志愿者进行伊曲康唑处理后的非靶向代谢组学分析,鉴定出58种显著变化的血浆代谢物,其中胆汁酸受影响最显著;甘氨猪去氧胆酸(GHCA)等胆汁酸及1βOH-DCA结合物在伊曲康唑处理后血浆暴露量降低约10倍,且GHCA个体间变异较小,体外实验支持其与CYP3A4活性的机制联系。
要点
- 伊曲康唑抑制CYP3A后,58种血浆代谢物显著改变,胆汁酸变化最突出。
- GHCA、GUDCA及1βOH-DCA结合物血浆暴露量降低约10倍(P<0.001)。
- GHCA个体间变异较低,体外证实CYP3A4选择性羟化GCDCA生成GHCA。
核心结论
- 伊曲康唑抑制CYP3A后,血浆代谢组发生广泛变化,胆汁酸类代谢物显著降低,其中GHCA等可作为有机制支持的内源性CYP3A活性生物标志物候选。
研究设计与样本
- 固定序列药物相互作用研究,纳入11名健康志愿者,给予伊曲康唑后开展非靶向代谢组学分析及靶向定量验证。
主要发现
- 非靶向代谢组学鉴定出58种血浆代谢物显著变化(变化>1.5倍或<0.67倍,P<0.05),胆汁酸受影响最显著,内源性大麻素类、黄嘌呤代谢及食物来源代谢物也有改变。
- 亚油酰乙醇酰胺和N-亚油酰甘氨酸等内源性大麻素组代谢物血浆水平升高2.4至6.0倍(P<0.05)。
- 甘氨熊去氧胆酸(GUDCA)和甘氨猪胆酸(GHCA)等胆汁酸在伊曲康唑处理后降低2.6至12.5倍(P<0.01)。
- 靶向定量显示GHCA、GUDCA和1βOH-DCA结合物血浆暴露量降低约10倍(P<0.001),GHCA个体间变异较低。
- 体外实验显示CYP3A4选择性羟化甘氨鹅去氧胆酸(GCDCA)生成GHCA,支持其与CYP3A4活性的机制联系。
临床怎么用
- GHCA等胆汁酸代谢物有望作为评估CYP3A活性和药物相互作用风险的内源性生物标志物,但需在多种CYP3A抑制剂中进一步验证。
局限性
- 研究仅纳入11名健康志愿者,样本量有限,且仅评估伊曲康唑一种CYP3A抑制剂,新标志物的转化应用需在更广泛人群和多种抑制剂中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reliable endogenous biomarkers for assessing CYP3A activity and clinical drug-drug interaction (DDI) risk remain limited. We characterized global metabolomic changes following itraconazole treatment in a fixed-sequence DDI study (11 healthy volunteers) to identify novel CYP3A endogenous biomarkers. Untargeted metabolomic analysis identified 58 plasma metabolites that were significantly modulated (changed by > 1.5-fold or < 0.67-fold, P < 0.05), highlighting the dynamic and systemic impact of CYP3A inhibition on the human metabolome. Bile acids represented the most prominently affected analytes, whereas changes were also observed in endocannabinoids, xanthine metabolism, and food-derived metabolites, revealing both on-target and potential off-target effects of itraconazole. For example, plasma levels of endocannabinoidome metabolites such as linoleoyl ethanolamide and N-linoleoylglycine increased by 2.4- to 6.0-fold (P < 0.05), while bile acids including glycoursodeoxycholate (GUDCA) and glycohyocholate (GHCA) decreased by 2.6- to 12.5-fold (P < 0.01) following itraconazole treatment. Targeted quantification was subsequently performed for the bile acids identified from untargeted analysis and the emerging CYP3A biomarkers, 1β-hydroxy-deoxycholic acid (1βOH-DCA) and its glycine and taurine conjugates. Notably, GHCA, GUDCA and 1βOH-DCA conjugates exhibited pronounced reduction in plasma exposure (~10-fold, P < 0.001) in the itraconazole treatment group. GHCA exhibited lower inter-individual variability than others. In vitro characterization demonstrated CYP3A4-selective hydroxylation of glycochenodeoxycholate to form GHCA, supporting its mechanistic linkage to CYP3A4 activity. Collectively, these findings expand the repertoire of sensitive and mechanistically supported endogenous biomarkers of CYP3A activity. Further evaluation of the newly identified GHCA and emerging bile acid metabolites across diverse CYP3A inhibitors can strengthen their translational utility in DDI risk assessment and drug development.
引用
- Yee SW, Kadar EP, Cerny MA, et al. Untargeted Metabolomics Reveal New Endogenous Plasma Biomarkers Associated with CYP3A Inhibition in Humans. Clin Pharmacol Ther. 2026. PMID: 42778994. doi:10.1002/cpt.70489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。